
R. Daniel Beauchamp, M.D., F.A.C.S.
- Co-Leader, Gastrointestinal Cancer Research Program
- John Clinton Foshee Distinguished Professor of Surgery (Surgical Oncology)
- Professor of Cell and Developmental Biology
Phone
D-4316 Medical Center North
Nashville, TN 37232-2729
R. Daniel Beauchamp, M.D., F.A.C.S.
- Co-Leader, Gastrointestinal Cancer Research Program
- John Clinton Foshee Distinguished Professor of Surgery (Surgical Oncology)
- Professor of Cell and Developmental Biology
615-322-2363
daniel.beauchamp@vumc.org
D-4316 Medical Center North
Nashville, TN 37232-2729
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Beauchamp is the John Clinton Foshee Distinguished Professor of Surgery and a Professor of Cell and Developmental Biology. He also serves co-leader of the Gastrointestinal Cancer Research Program. Dr. Beauchamp is the former Chair of the Section of Surgical Sciences and Surgeon-in-Chief of Vanderbilt University Hospital, holding these positions from July 2001 to July 2018. His clinical practice encompassed Surgical Oncology including GI cancers, melanoma, sarcomas and breast cancer for almost 20 years, but is currently focused on breast cancer.
Dr. Beauchamp has two active R01 grants from NIH, and co-leads one of the main projects in the GI Cancer SPORE. His primary area of research interest has been in colorectal carcinogenesis, the biology of cancer cell invasion and metastasis, and in the identification of novel molecular biomarkers and therapeutic targets in colorectal and other alimentary tract malignancies. His work applies genomic, transcriptomic and proteomic technology to identify novel biomarkers and therapeutic targets in colorectal cancer. He also uses molecular genetics, chemical biology and cell biological approaches to examine mechanistic questions in cancer biology in both cell culture and mouse models. They have also developed a chemical biology project and have identified probes that inhibit Epithelial-to-Mesenchymal transition and restore E-cadherin expression in cells in which E-cadherin transcription is repressed. In addition to the basic cancer research, Dr. Beauchamp works in collaboration with his Medical Oncology and Radiation Oncology colleagues to accrue cancer patients to approved cancer clinical trials. He has trained and mentored numerous junior faculty members, physician scientist fellows, medical students, graduate students and post-doctoral fellows in his laboratory.
Education
- M.D., The University of Texas Medical Branch, Galveston, Texas (1982)
- B.S., Texas Tech University, Lubbock, Texas, (1978)
Research Emphasis
Transforming growth factor, Gastrointestinal carcinogenesis, Ras oncogene, colon cancer, epithelial to mesenchymal transition, metastasis, mouse models
Research Description
R. Daniel Beauchamp, MD, is the John Clinton Foshee Distinguished Professor of Surgery. He served as Chairman of the Section of Surgical Sciences, and Surgeon-in-Chief of Vanderbilt University Hospital from July 2001 through June 2018. He has been a full-time faculty member at Vanderbilt since December 1994. He holds joint appointment as professor in the department of Cell and Developmental Biology. He also served as Deputy Director of the Vanderbilt-Ingram Cancer Center from 2011 to 2019 and serves as Gastrointestinal Cancer Program Co-Leader since 2014. He was appointed Vice President for Cancer Center Network Affairs in 2018. Dr. Beauchamp has had longstanding funding support for his research from the NIH, and co-leads one of the main projects in the GI Cancer SPORE. Dr. Beauchamp's primary area of research interest has been in colorectal carcinogenesis, the biology of cancer cell invasion and metastasis, and in the identification of novel molecular biomarkers and therapeutic targets in colorectal and other alimentary tract malignancies. He applies molecular genetics, chemical biology and cell biological approaches to examine mechanistic questions in cancer biology in human tissue samples, 2D and 3D cell culture and mouse models. In addition to the basic cancer research Dr. Beauchamp works in collaboration with his Medical Oncology and Radiation Oncology colleagues to accrue cancer patients to approved clinical trials. He has trained and mentored numerous junior faculty members, physician scientist fellows, medical students, graduate students and post-doctoral fellows in his laboratory. He is a member of the American Society for Clinical Investigation, the National Academy of Medicine and a fellow of the American Association for the Advancement of Science.
Publications
- Wang-Bishop L, Chen Z, Gomaa A, Lockhart AC, Salaria S, Wang J, Lewis KB, Ecsedy J, Washington K, Beauchamp RD, El-Rifai W. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1. Gastroenterology [print-electronic]. 2019 Feb; 156(3): 662-675.e7. PMID: 30342037, PMCID: PMC6368861, PII: S0016-5085(18)35161-8, DOI: 10.1053/j.gastro.2018.10.030, ISSN: 1528-0012.
- Saito-Diaz K, Benchabane H, Tiwari A, Tian A, Li B, Thompson JJ, Hyde AS, Sawyer LM, Jodoin JN, Santos E, Lee LA, Coffey RJ, Beauchamp RD, Williams CS, Kenworthy AK, Robbins DJ, Ahmed Y, Lee E. APC Inhibits Ligand-Independent Wnt Signaling by the Clathrin Endocytic Pathway. Dev. Cell. 2018 Mar 3/12/2018; 44(5): 566-581.e8. PMID: 29533772, PMCID: PMC5884143, PII: S1534-5807(18)30108-4, DOI: 10.1016/j.devcel.2018.02.013, ISSN: 1878-1551.
- Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol [print-electronic]. 2018 Feb; 117(2): 284-9. PMID: 28940307, DOI: 10.1002/jso.24834, ISSN: 1096-9098.
- Means AL, Freeman TJ, Zhu J, Woodbury LG, Marincola-Smith P, Wu C, Meyer AR, Weaver CJ, Padmanabhan C, An H, Zi J, Wessinger BC, Chaturvedi R, Brown TD, Deane NG, Coffey RJ, Wilson KT, Smith JJ, Sawyers CL, Goldenring JR, Novitskiy SV, Washington MK, Shi C, Beauchamp RD. Epithelial Smad4 Deletion Up-Regulates Inflammation and Promotes Inflammation-Associated Cancer. Cell Mol Gastroenterol Hepatol. 2018; 6(3): 257-76. PMID: 30109253, PMCID: PMC6083016, PII: S2352-345X(18)30082-1, DOI: 10.1016/j.jcmgh.2018.05.006, ISSN: 2352-345X.
- Padmanabhan C, Rellinger EJ, Zhu J, An H, Woodbury LG, Chung DH, Waterson AG, Lindsley CW, Means AL, Beauchamp RD. CFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition. Oncotarget. 2017 Nov 11/24/2017; 8(60): 101072-86. PMID: 29254146, PMCID: PMC5731856, PII: 19557, DOI: 10.18632/oncotarget.19557, ISSN: 1949-2553.
- Rellinger EJ, Padmanabhan C, Qiao J, Craig BT, An H, Zhu J, Correa H, Waterson AG, Lindsley CW, Beauchamp RD, Chung DH. Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. Oncotarget. 2017 Oct 10/31/2017; 8(53): 91040-51. PMID: 29207623, PMCID: PMC5710904, PII: 19406, DOI: 10.18632/oncotarget.19406, ISSN: 1949-2553.
- Rellinger EJ, Padmanabhan C, Qiao J, Appert A, Waterson AG, Lindsley CW, Beauchamp RD, Chung DH. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand. Biochem. Biophys. Res. Commun [print-electronic]. 2017 Sep 9/16/2017; 491(2): 463-8. PMID: 28716733, PII: S0006-291X(17)31392-X, DOI: 10.1016/j.bbrc.2017.07.050, ISSN: 1090-2104.
- Ma Y, Wang L, Neitzel LR, Loganathan SN, Tang N, Qin L, Crispi EE, Guo Y, Knapp S, Beauchamp RD, Lee E, Wang J. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. Clin. Cancer Res [print-electronic]. 2017 Apr 4/15/2017; 23(8): 2027-37. PMID: 27678457, PMCID: PMC5368030, PII: 1078-0432.CCR-16-0453, DOI: 10.1158/1078-0432.CCR-16-0453, ISSN: 1078-0432.
- Gonzalez RS, Huh WJ, Cates JM, Washington K, Beauchamp RD, Coffey RJ, Shi C. Micropapillary colorectal carcinoma: clinical, pathological and molecular properties, including evidence of epithelial-mesenchymal transition. Histopathology [print-electronic]. 2017 Jan; 70(2): 223-31. PMID: 27560620, DOI: 10.1111/his.13068, ISSN: 1365-2559.
- Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X. Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples. Sci Rep. 2016 Sep 9/14/2016; 6: 33273. PMID: 27623752, PMCID: PMC5021945, PII: srep33273, DOI: 10.1038/srep33273, ISSN: 2045-2322.